Euro VC Fountain unveils a $101M biotech fund

Fountain Healthcare Partners put together an €85 million ($101 million) new purse, money the Irish investor plans to pour into biotech startups. Fountain plans to invest more than 75% of its cash in Europe, expecting to make between 10 and 15 deals in total, the firm said. The new fund exceeded Fountain's goal of €75 million ($89 million), and now the group is seeking additional investors to close it out at a hard cap of €125 million ($148 million). Among Fountain's portfolio companies are Civitas Therapeutics, Innocoll and Genable Technologies. More

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.